But all of this is still very new in terms of how to manage patients effectively.For the study, researchers looked at the use of semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) among patients undergoing weight-loss surgery, analyzing nearly 365,000 patients between 2018 and 2024.The proportion of patients who received at least one GLP-1 prescription in the year leading up to their surgery exploded to more than 29% in the fourth quarter of 2024 from just under 2% in the first quarter of 2020, results show.Among patients without type 2 diabetes, GLP-1 drug use before weight-loss surgery increased to 23% in the fourth quarter of 2024 from 2% in the first quarter of 2020, researchers found.GLP-1 use among patients with type 2 diabetes was even higher, rising to 45% from 11% during the same period.The median age of the patients was 43, and they had a median preoperative body mass index (BMI) of 46
With conditions, we definitely need more research where we could say that GLP-1 caused this
2,5,8-10,12,13 As research advances, these insights highlight the potential of nutrition science to inform future GLP-1-targeted therapies and sustainable strategies for metabolic health
In the process of neurodegeneration, the phagocytic function of microglia is beneficial in clearing debris and protein aggregates, but the clearance of live synapses and neurons is harmful (Butler et al., 2021)
Hydration: Drink plenty of water and consider electrolytes to manage nausea
Science is moving fast, and if the past 20 years are anything to go by, we havent seen the full potential yet
